S&CO Inc. purchased a new position in Agios Pharmaceuticals Inc (NASDAQ:AGIO) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 3,400 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.
Several other large investors also recently modified their holdings of AGIO. Quantamental Technologies LLC acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $28,000. Advisor Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 33.1% in the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 297 shares during the period. ETF Managers Group LLC lifted its stake in shares of Agios Pharmaceuticals by 15.7% in the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 216 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Agios Pharmaceuticals by 14.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 430 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $188,000. 98.78% of the stock is owned by institutional investors.
In other news, insider Scott Biller sold 9,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $65.00, for a total transaction of $585,000.00. Following the completion of the sale, the insider now owns 28,277 shares in the company, valued at approximately $1,838,005. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Bowden sold 10,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $64.16, for a total transaction of $641,600.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,000 shares of company stock valued at $2,765,530. 3.02% of the stock is owned by insiders.
Shares of NASDAQ:AGIO traded up $0.29 during mid-day trading on Thursday, hitting $57.12. The stock had a trading volume of 3,006 shares, compared to its average volume of 370,452. The company has a market cap of $3.44 billion, a PE ratio of -9.42 and a beta of 2.38. Agios Pharmaceuticals Inc has a 12-month low of $41.63 and a 12-month high of $99.82.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.65) by $0.07. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $19.98 million. Agios Pharmaceuticals had a negative net margin of 366.61% and a negative return on equity of 44.13%. The firm’s quarterly revenue was up 200.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.81) EPS. As a group, sell-side analysts predict that Agios Pharmaceuticals Inc will post -6.73 EPS for the current year.
AGIO has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. ValuEngine lowered shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 4th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, January 17th. Piper Jaffray Companies cut their target price on shares of Agios Pharmaceuticals to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 14th. Finally, Leerink Swann upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, February 15th. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $97.86.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.
Featured Article: What is insider trading?
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.